~ We are using next generation sequencing strategies to map the epigenome during cell cycle.
~ We are identifying chromatin and non-coding RNAs that are regulating cell cycle progression.
~ We are assessing whether there are other chromatin regulators involved in protein synthesis.
~ We are determining whether other chromatin factors enhance mTOR inhibitor sensitivity or other cancer therapies.
~ We are studying other coding SNPs in chromatin modifiers that impact drug response and patient stratification.
~ We use genetic features or molecular mechanisms downstream of chromatin regulators to stratify and optimally treat cancer patients.
Epigenetic Mechanisms Driving Copy Gain, Amplifications and Drug Resistance
Epigenetic Mechanisms Regulating Cell Cycle Progression
Copyright © Whetstine Laboratory. All rights reserved.
~ We are asking what cellular cues or exposures are involved in driving copy gain of regions promoting drug resistance and tumorigenesis. These same questions are being extended to other clinically relevant amplified oncogenes.
~ We are identifying all known signaling and epigenetic-related pathways involved in driving copy gain and amplifications.
~ We are identifying the epigenetic states associated with the genome that have a propensity to undergo copy number changes.
~ We are screening for factors that will allow these copy gains to be inherited.
~ We are collaborating with clinicians to establish the optimal patients for using epigenetic therapies targeting pathways promoting copy gain and drug resistance.
Epigenetic Mechanisms Impacting Cancer Therapy